Loading...

Fundamental Neuropathology for Pathologists and Toxicologists: Principles and Techniques

ISBN: 978-0-470-22733-6

September 2011

624 pages

Description

Grasp the fundamentals behind neuropathology

Fundamental Neuropathology for Pathologists and Toxicologists: Principles and Techniques provides an introduction to the discipline and techniques of neuropathology. Aimed not only at pathologists and toxicologists, but more broadly at comparative neurotoxicologists, environmental scientists, students, and other experts working in the scientific and medical worlds as well, the book is an invaluable guide to understanding diseases of the central and peripheral nervous systems.

With a focus on the practical applications of assessing chemical toxicity, the book addresses both the fundamentals of neuropathology, and provides detailed coverage of current practices in anatomic, biochemical, clinical, and molecular analyses. In addition, it examines the practical aspects of neuropathology, such as study design data interpretation, regulatory considerations, and tips for preparing reports.

Describing the intricacies of the nervous system and the standard testing procedures that help toxicologists make neuropathological evaluations, Fundamental Neuropathology for Pathologists and Toxicologists is essential reading for anyone interested in understanding the chemical, environmental, biological, medical, and regulatory details important for analyzing toxicant-induced neurodiseases.

About the Author
BRAD BOLON, DVM, MS, PhD, Diplomate ACVP, Diplomate ABT, Fellow ATS, Fellow IATP, has spent over twenty years as a practitioner and teacher of toxicologic neuropathology. He is the founder of GEMpath, Inc., an experimental pathology consultancy specializing in drug discovery research.

MARK T. BUTT, DVM, Diplomate ACVP, is the founder of Tox Path Specialists, LLC, a company that provides neuropathology and histology support to pharmaceutical and biotechnology firms developing novel therapies that target nervous system diseases. He has over twenty years' experience providing neuropathology support and has evaluated over four hundred studies supporting regulatory submissions for neuroactive compounds.